Actively Recruiting
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
Led by Lund University Hospital · Updated on 2025-09-10
300
Participants Needed
4
Research Sites
204 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
There are several ways of personalizing PRRT (peptide receptor radionuclide treatment) in NEN (neuroendocrine neoplasia). Nevertheless, the current treatment regimen is not personalized. This trial aims to compare personalized PRRT to non-personalized PRRT in terms of safety, efficacy and resource demands in order to optimize treatment outcomes in an evidence-based manner in future.
CONDITIONS
Official Title
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age ≥18 years
- Written informed consent
- Eastern Cooperative Oncology Group (ECOG) 0-1
- Presence of histologically confirmed, advanced, well-differentiated, inoperable neuroendocrine tumors (NET) of any primary tumor origin and any grade, except for pheochromocytoma and paraganglioma.
- Somatostatine receptor (SSTR)-expression in tumor lesions > basal liver uptake on 68Ga-DOTA-PET
- Radiologically progressive disease within the last 1-24 months according to common clinical criteria and confirmed by the institutional multidisciplinary conference for the treatment of NETs. The CT/MRI that shows tumor progression compared to screening/baseline must have been performed 1-24 months earlier.
- All previous anti-tumor treatment except SSA must be terminated at least 4 weeks before start of treatment within the trial.
- Measurable disease according to RECIST v 1.1
- Given the available, approved anti-tumor treatments and the specific characteristics of the patient and the tumor, the investigator judges peptide receptor radionuclide therapy (PRRT) to be the treatment of choice
- GFR > 50 ml/min/1.73 m2 as determined by iohexol- or 51Cr-EDTA clearance, calculated according to a combination of LMR18 and CAPA formulas, or equally accurate method
- Hemoglobin > 90 g/L, platelets >100 x109/L, leukocytes > 3.0x109/L, neutrophils > 1.5 x109/L, aspartate transaminase (ASAT)/alanine aminotransferase (ALAT) < 3 x ULN, bilirubin < 2 x upper limit of normal (ULN), albumin > 25 g/L
- For women of child-bearing potential, highly effective contraception should be used from the time of inclusion up to at least six months after the end of treatment (EOT) visit.
You will not qualify if you...
- Pregnancy or lactation
- Previous treatment with PRRT
- Concomitant systemic anti-tumor therapy other than somatostatin analogue (SSA)
- Contraindications for treatment with capecitabine according to the approved label.
- Discordance between CT/MRI/18F-FDG-PET and 68Ga-DOTA-PET, with evidence of tumor lesions without uptake on 68Ga-DOTATOC.
- Any other serious, uncontrolled medical or psychiatric condition that, in the opinion of the investigator, precludes the patient from participation in the trial
- Unwillingness, or inability, to participate in any part of the trial procedures or treatments.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Sahlgrenska University Hospital, Dept. of Oncology
Gothenburg, Sweden
Actively Recruiting
2
Skåne University Hospital, Dept. of Oncology
Lund, Sweden, SE-226 52
Actively Recruiting
3
Karolinska University Hospital, Dept. of Oncology
Stockholm, Sweden, SE-171 76
Actively Recruiting
4
Accademical Hospital, Uppsala, Dept. of Oncology
Uppsala, Sweden, SE-752 37
Actively Recruiting
Research Team
P
Pernilla Asp, MD, Senior consultant
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here